Sema3A promotes the resolution of cardiac inflammation after myocardial infarction

Marieke Rienks, Paolo Carai, Nicole Bitsch, Mark W.m. Schellings, Maarten Vanhaverbeke, Johan Verjans, Ilona Cuijpers, Stéphane Heymans, Anna PapageorgiouBasic 2017 · DOI

TL;DR

This study reveals that Semaphorin 3A (Sema3A) plays a crucial role in resolving inflammation after heart attacks, leading to improved cardiac function. By promoting the clearance of inflammatory cells and shifting macrophages towards a reparative state, Sema3A facilitates better healing and reduces adverse cardiac remodeling.

What Problem Does This Paper Address?

Following a heart attack (myocardial infarction, MI), the body initiates an inflammatory response to clear damaged tissue and begin repair. However, prolonged or excessive inflammation can lead to detrimental scarring and heart failure. While the signals that initiate this inflammatory response are well-studied, the mechanisms that resolve it and transition the heart to a healing phase are less understood. This paper investigates the role of Semaphorin 3A (Sema3A), a molecule previously known for its roles in nerve development and immune regulation, in this critical resolution phase after MI. Understanding these resolution mechanisms is key to developing new therapies to prevent heart failure after heart attacks.

Methods

The researchers employed a multi-pronged approach:

  • Human Patient Data: They analyzed blood samples from patients who had experienced a myocardial infarction to measure Sema3A and Cx3CR1 (a marker for reparative monocytes) expression over time.
  • Murine Model of Myocardial Infarction: They used genetically modified mice that were heterozygous for Sema3A (Sema3A HZ) and compared them to wild-type (WT) littermates. This allowed them to study the effects of reduced Sema3A levels on cardiac healing after experimentally induced heart attacks.
  • Histological and Immunohistochemical Analysis: Heart tissues from these mice were examined to quantify infarct size, collagen deposition, capillary density, and the presence of immune cells (leukocytes and macrophages).
  • Echocardiography: This non-invasive imaging technique was used to assess cardiac function (e.g., fractional shortening) in the mouse models.
  • In Vitro Macrophage Assays: Bone marrow-derived macrophages were cultured and stimulated to investigate Sema3A's direct effects on macrophage polarization (shifting from pro-inflammatory to anti-inflammatory/resolution states), apoptosis (programmed cell death), and efferocytosis (the clearance of dead cells).
  • Chemotaxis Assays: Experiments were conducted to assess the migration of monocytes in response to chemoattractants, both in the presence and absence of Sema3A.
  • Western Blot and RT-PCR: These molecular techniques were used to measure the expression levels of various proteins and genes related to inflammation, apoptosis, and macrophage markers.

Datasets

The study utilized two primary "datasets":

  1. Human Patient Samples: Blood samples from 11 patients with acute coronary syndrome, collected at admission, 3 days, and 30 days post-MI.
  2. Murine Models: Data derived from experiments on Sema3A heterozygous (HZ) and wild-type (WT) mice subjected to a myocardial infarction model.

No new benchmarks were introduced; the study focused on analyzing existing biological processes and molecular markers in these specific contexts.

Key Insights and Ideas

  • Sema3A as a Resolution Signal: The study strongly suggests that Sema3A is not just present during inflammation but actively promotes its resolution, a critical step for effective cardiac healing.
  • Monocyte-Sema3A Link: Increased Sema3A expression in circulating monocytes of human patients post-MI, coinciding with increased Cx3CR1 (a marker of reparative monocytes), highlights a potential diagnostic or therapeutic link.
  • Sema3A's Dual Role in Macrophages: Sema3A appears to have a dual effect on macrophages: it induces apoptosis in pro-inflammatory (M1) macrophages and promotes their transition to a resolution-phase phenotype, enhancing their ability to clear debris (efferocytosis).
  • Constraining Inflammation: Beyond its role in macrophage reprogramming, Sema3A also seems to limit the initial recruitment of monocytes to the injured heart.
  • Functional Impact: Reduced Sema3A in HZ mice led to impaired cardiac function and thinner infarcts, underscoring the clinical relevance of Sema3A-mediated resolution.

Key Results

  • Human Patients: Circulating monocyte expression of Sema3A and Cx3CR1 significantly increased by 30 days post-MI.
  • Murine Models:
    • Sema3A HZ mice showed significantly reduced cardiac function (fractional shortening) compared to WT mice 14 days post-MI, despite similar infarct sizes.
  • Sema3A HZ mice had a greater number of leukocytes in the border zone at 3 days post-MI and in the infarct zone at 14 days post-MI, indicating increased inflammation.
  • In vitro, recombinant Sema3A inhibited monocyte migration and induced apoptosis in classical (M1) macrophages, while promoting their polarization to resolution-phase macrophages and enhancing efferocytosis.
  • Sema3A HZ mice showed reduced expression of apoptotic markers (cleaved caspase-3) in the infarcted area compared to WT mice.

Limitations and Future Work

  • In Vivo Macrophage Phenotyping: While the study provides strong in vitro evidence for Sema3A's effects on macrophage polarization, definitively characterizing these phenotypes in vivo remains challenging due to the dynamic and context-dependent nature of macrophage populations. The authors acknowledge that the "authenticity of well-defined M1 and M2 macrophage populations in vivo is still of ongoing debate."
  • Broader Cell Involvement: The authors note that while their study focused on monocytes/macrophages, they couldn't provide "substantial evidence that will allow us to ascribe the effect of Sema3A in response to ischemic induced myocardial injury exclusively to monocytes/macrophages." This suggests other cell types might also be involved.
  • Therapeutic Potential: The study strongly suggests Sema3A could be a therapeutic target for preventing heart failure by limiting adverse cardiac remodeling. Future work could explore direct therapeutic administration of Sema3A or strategies to upregulate its endogenous production post-MI.
  • Mechanistic Details: Further investigation into the specific downstream signaling pathways activated by Sema3A in macrophages and other cardiac cells would be beneficial.

Summary updated

Abstract

Optimal healing after myocardial infarction requires not only the induction of inflammation, but also its timely resolution. In patients, 30 days post myocardial infarction, circulating monocytes have increased expression of Semaphorin3A (Sema3A) as compared to directly after admission. This increased expression coincides with increased expression of Cx3CR1-a marker of non-classical monocytes that are important for immune resolution hence proper wound healing. In mice, the expression of Sema3A also increases in response to myocardial ischemia being expressed by infiltrating leukocytes. Comparing Sema3A heterozygote (HZ) and wild type (WT) mice post myocardial infarction, revealed increased presence of leukocytes in the cardiac tissues of HZ mice as compared to WT, with no differences in capillary density, collagen deposition, cardiomyocyte surface area, chemokine-or adhesion molecules expression. Whilst infarct sizes were similar 14 days after myocardial infarction in both genotypes, Sema3A HZ mice had thinner infarcts and reduced cardiac function as compared to their WT littermates. In vitro experiments were conducted to study the role of Sema3A in inflammation and resolution of inflammation as a potential explanation for the differences in leukocyte recruitment and cardiac function observed in our in vivo experiments. Here, recombinant Sema3A protein was able to affect the pro-inflammatory state of cultured bone marrow derived macrophages. First, the pro-inflammatory state was altered by the induced apoptosis of classical macrophages in the presence of Sema3A. Second, Sema3A promoted the polarization of classical macrophages to resolution-phase macrophages and enhanced their efferocytotic ability, findings that were reflected in the infarcted cardiac tissue of the Sema3A HZ mice. Finally, we demonstrated that besides promoting resolution of inflammation, Sema3A was also able to retard the migration of monocytes to the myocardium. Collectively our data demonstrate that Sema3A reduces cardiac inflammation and improves cardiac function after myocardial infarction by promoting the resolution of inflammation.
BibTeX
@inproceedings{rienks2017sema,
  author = {Marieke Rienks and Paolo Carai and Nicole Bitsch and Mark W.M. Schellings and Maarten Vanhaverbeke and Johan Verjans and Ilona Cuijpers and Stéphane Heymans and Anna Papageorgiou},
  title = {{Sema3A promotes the resolution of cardiac inflammation after myocardial infarction}},
  booktitle = {Basic},
  year = {2017},
  doi = {10.1007/s00395-017-0630-5},
}
Figure